Abstract
Obesity is a chronic, relapsing disease, with complex determinants promoting the incidence of conditions such as type 2 diabetes (T2D), cardiovascular diseases (CVD) and cancer. A significant body of literature exists in the molecular understanding of obesity, with continued investment in pharmacotherapy anti-obesity medications (AOM’s), yet obesity is largely resistant to therapy (Muller, 2021) without an integrated; personalised approach (Son, 2020).
General Practitioners (GP’s) and other healthcare providers have a vital role to play in identifying, reducing, and managing the adverse health effects of environmental pollution in the community. Environmental pollutants from pharmacotherapy options available to treat obesity add to overall societal exposure and ecological impact in aquatic environments (Tchang, 2021).
General Practitioners (GP’s) and other healthcare providers have a vital role to play in identifying, reducing, and managing the adverse health effects of environmental pollution in the community. Environmental pollutants from pharmacotherapy options available to treat obesity add to overall societal exposure and ecological impact in aquatic environments (Tchang, 2021).
| Original language | English |
|---|---|
| Publication status | Published - 15 Dec 2021 |
Keywords
- environmental pollution
- Public health
- Obesity
- Pharmaceuticals